BMJ Best Practice

参考文献

关键文献

Merle NS, Church SE, Fremeaux-Bacchi V, et al. Complement system part I - molecular mechanisms of activation and regulation. Front Immunol. 2015 Jun 2;6:262.

Merle NS, Noe R, Halbwachs-Mecarelli L, et al. Complement system part II: role in immunity. Front Immunol. 2015 May 26;6:257.

Grumach AS, Kirschfink M. Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol Immunol. 2014 Oct;61(2):110-7.

Unsworth DJ. Complement deficiency and disease. J Clin Pathol. 2008 Sep;61(9):1013-7.

参考文章

1.  Merle NS, Church SE, Fremeaux-Bacchi V, et al. Complement system part I - molecular mechanisms of activation and regulation. Front Immunol. 2015 Jun 2;6:262.

2.  Merle NS, Noe R, Halbwachs-Mecarelli L, et al. Complement system part II: role in immunity. Front Immunol. 2015 May 26;6:257.

3.  Hajishengallis G, Reis ES, Mastellos DC, et al. Novel mechanisms and functions of complement. Nat Immunol. 2017 Nov 16;18(12):1288-8.

4.  Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol. 2013 Apr 15;190(8):3831-8.

5.  Pettigrew HD, Teuber SS, Gershwin ME. Clinical significance of complement deficiencies. Ann N Y Acad Sci. 2009 Sep;1173:108-23.

6.  Degn SE, Jensenius JC, Thiel S. Disease-causing mutations in genes of the complement system. Am J Hum Genet. 2011 Jun 10;88(6):689-705.

7.  Skattum L, Van deuren M, Van der poll T, et al. Complement deficiency states and associated infections. Mol Immunol. 2011 Aug;48(14):1643-55.

8.  Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev. 1991 Jul;4(3):359-95.

9.  European Society for Immunodeficiencies. Registry Working Party: ESID database statistics. June 2018 [internet publication].

10.  Grumach AS, Kirschfink M. Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol Immunol. 2014 Oct;61(2):110-7.

11.  Gompels MM, Lock RJ, Albinun M, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol. 2005;139:379-394.

12.  Walport MJ. Complement: first of two parts. N Engl J Med. 2001 Apr 5;344(14):1058-66.

13.  Walport MJ. Complement: second of two parts. N Engl J Med. 2001 Apr 12;344(15):1140-4.

14.  Unsworth DJ. Complement deficiency and disease. J Clin Pathol. 2008 Sep;61(9):1013-7.

15.  Caccia S, Suffritti C, Cicardi M. Pathophysiology of hereditary angioedema. Pediatr Allergy Immunol Pulmonol. 2014 Dec 1;27(4):159-63.

16.  Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-the 2017 revision and update. Allergy. 2018 Aug;73(8):1575-96.

17.  Breitbart SI, Bielory L, Breitbart SI, et al. Acquired angioedema: Autoantibody associations and C1q utility as a diagnostic tool. Allergy Asthma Proc. 2010 Sep-Oct;31(5):428-34.

18.  Bork K, Gül D, Hardt J, et al. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am J Med. 2007 Nov;120(11):987-92.

19.  Macedo AC, Isaac L. Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway. Front Immunol. 2016 Feb 24;7:55.

20.  Carroll MC. A protective role for innate immunity in systemic lupus erythematosus. Nat Rev Immunol. 2004 Oct;4(10):825-31.

21.  Lewis LA, Ram S. Meningococcal disease and the complement system. Virulence. 2014 Jan 1;5(1):98-126.

22.  Centers for Disease Control and Prevention. Recommended immunization schedule for children and adolescents aged 18 years or younger, United States, 2018. February 2018 [internet publication].

23.  Cook HT. Complement and kidney disease. Curr Opin Nephrol Hypertens. 2013 May;22(3):295-301.

24.  Noris M, Remuzzi G. Genetics of immune-mediated glomerular diseases: focus on complement. Semin Nephrol. 2017 Sep;37(5):447-63.

25.  Cook HT. C3 glomerulopathy. F1000Res. 2017 Mar 10;6:248.

26.  Jokiranta TS. HUS and atypical HUS. Blood. 2017 May 25;129(21):2847-56.

27.  Fritsche LG, Igl W, Bailey JN, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2016 Feb;48(2):134-43.

28.  Hill A, DeZern AE, Kinoshita T, et al. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017 May 18;3:17028.

29.  Gorevic PD. Rheumatoid factor, complement, and mixed cryoglobulinemia. Clin Dev Immunol. 2012;2012:439018.

30.  Levy Y, George J, Yona E, et al. Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon. Immunol Res. 1998 Aug;18(1):55-60.

31.  Prohászka Z, Nilsson B, Frazer-Abel A, et al. Complement analysis 2016: clinical indications, laboratory diagnostics and quality control. Immunobiology. 2016 Nov;221(11):1247-58.

32.  Seelen MA, Roos A, Wieslander J, et al. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods. 2005 Jan;296(1-2):187-98.

33.  Wehling C, Amon O, Bommer M, et al. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol. 2017 Feb;187(2):304-15.

34.  Licht C, Weyersburg A, Heinen S, et al. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis. 2005 Feb;45(2):415-21.

35.  Ricklin D, Mastellos DC, Reis ES, et al. The renaissance of complement therapeutics. Nat Rev Nephrol. 2018 Jan;14(1):26-47.

36.  Fakhouri F, Frémeaux-Bacchi V, Loirat C. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy. Eur J Intern Med. 2013 Sep;24(6):492-5.

使用此内容应接受我们的免责声明